Patents by Inventor Mary Ellen Rybak

Mary Ellen Rybak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination of ET-743 and a 5-fluorouracil pro-drug for cancer treatment
    Patent number: 7622458
    Abstract: Methods of treating a human body for cancer are provided. In one aspect, a therapeutic amount of capecitabine is administered in combination with ET-743 in a dose range between 0.75 and 1.4 mg/m2 for Et-743. In a related aspect, an effective therapeutic amount of ET-743 is administered in combination with capecitabine in a dose range between 1500 to 2500 mg/m/day for capecitabine.
    Type: Grant
    Filed: November 15, 2004
    Date of Patent: November 24, 2009
    Assignee: Pharma Mar, S.A.U.
    Inventor: Mary Ellen Rybak
  • Melanoma therapy
    Patent number: 7482014
    Abstract: Methods for treating treatment-naive as well as treatment-experienced patients having melanoma to increase the progression-free survival time involving administering a therapeutically effective amount of pegylated interferon-alpha, e.g., preferably pegylated interferon alpha-2b, as adjuvant therapy to definitive surgery are disclosed.
    Type: Grant
    Filed: June 24, 2005
    Date of Patent: January 27, 2009
    Assignee: Schering Corporation
    Inventors: Mary Ellen Rybak, Esther Helen Rose
  • COMBINED TUMOR SUPPRESSOR GENE THERAPY AND CHEMOTHERAPY IN THE TREATMENT OF NEOPLASMS
    Publication number: 20080286239
    Abstract: In one embodiment, this invention provides methods of treating mammalian cancer or hyperproliferative cells, said method comprising contacting said cells with a tumor suppressor protein or tumor suppressor nucleic acid and also contacting said cell with at least one adjunctive anti-cancer agent. The invention also provides for a pharmacological composition comprising a tumor suppressor protein or a tumor suppressor nucleic acid and at least one adjunctive anti-cancer agent, and a kit for the treatment of mammalian cancer or hyperproliferative cells.
    Type: Application
    Filed: May 28, 2008
    Publication date: November 20, 2008
    Applicant: Canji, Inc.
    Inventors: Loretta Nielsen, Jo Ann Horowitz, Daniel C. Maneval, G. William Demers, Mary Ellen Rybak, Gene Resnick
  • Melanoma therapy
    Patent number: 6923966
    Abstract: Methods for treating treatment-naive as well as treatment-experienced patients having melanoma to increase the progression-free survival time involving administering a therapeutically effective amount of pegylated interferon-alpha, e.g., preferably pegylated interferon alpha-2b, as adjuvant therapy to definitive surgery are disclosed.
    Type: Grant
    Filed: July 12, 2001
    Date of Patent: August 2, 2005
    Assignee: Schering Corporation
    Inventors: Mary Ellen Rybak, Esther Helen Rose
  • Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
    Publication number: 20040235736
    Abstract: In one embodiment, this invention provides methods of treating mammalian cancer or hyperproliferative cells, said method comprising contacting said cells with a tumor suppressor protein or tumor suppressor nucleic acid and also contacting said cell with at least one adjunctive anti-cancer agent. The invention also provides for a pharmacological composition comprising a tumor suppressor protein or a tumor suppressor nucleic acid and at least one adjunctive anti-cancer agent, and a kit for the treatment of mammalian cancer or hyperproliferative cells.
    Type: Application
    Filed: April 13, 2004
    Publication date: November 25, 2004
    Applicant: CANJI, INC.
    Inventors: Loretta Nielsen, Jo Ann Horowitz, Daniel C. Maneval, G. William Demers, Mary Ellen Rybak, Gene Resnick
  • Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
    Publication number: 20030064949
    Abstract: In one embodiment, this invention provides methods of treating mammalian cancer or hyperproliferative cells, said method comprising contacting said cells with a tumor suppressor protein or tumor suppressor nucleic acid and also contacting said cell with at least one adjunctive anti-cancer agent. The invention also provides for a pharmacological composition comprising a tumor suppressor protein or a tumor suppressor nucleic acid and at least one adjunctive anti-cancer agent, and a kit for the treatment of mammalian cancer or hyperproliferative cells.
    Type: Application
    Filed: February 28, 2002
    Publication date: April 3, 2003
    Inventors: Loretta Nielsen, Jo Ann Horowitz, Daniel C. Maneval, G. William Demers, Mary Ellen Rybak, Gene Resnick
  • COMBINED TUMOR SUPPRESSOR GENE THERAPY AND CHEMOTHERAPY IN THE TREATMENT OF NEOPLASMS
    Publication number: 20030060434
    Abstract: In one embodiment, this invention provides methods of treating mammalian cancer or hyperproliferative cells, said method comprising contacting said cells with a tumor suppressor protein or tumor suppressor nucleic acid and also contacting said cell with at least one adjunctive anti-cancer agent. The invention also provides for a pharmacological composition comprising a tumor suppressor protein or a tumor suppressor nucleic acid and at least one adjunctive anti-cancer agent, and a kit for the treatment of mammalian cancer or hyperproliferative cells.
    Type: Application
    Filed: May 13, 1999
    Publication date: March 27, 2003
    Inventors: LORETTA NIELSEN, JO ANN HOROWITZ, DANIEL C. MANEVAL, G. WILLIAM DEMERS, MARY ELLEN RYBAK, GENE RESNICK
  • CML Therapy
    Patent number: 6362162
    Abstract: Methods for treating treatment-naive as well as treatment-experienced patients having CML to achieve at least a partial cytogenetic response involving administering a therapeutically effective amount of pegylated interferon-alpha, e.g., pegylated interferon alpha-2b as monotherapy or in association with a therapeutically effective amount of Ara-C are disclosed.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: March 26, 2002
    Assignee: Schering Corporation
    Inventors: Mary Ellen Rybak, Esther Helen Rose
  • Renal cell carcinoma treatment
    Publication number: 20010053548
    Abstract: Methods for treating treatment-naive as well as treatment-experienced patients having RCC to achieve at least a partial tumor response involving administering a therapeutically effective amount of pegylated interferon-alpha, e.g., pegylated interferon alpha-2b as monotherapy or in association with a therapeutically effective amount of IL-2 are disclosed.
    Type: Application
    Filed: July 9, 2001
    Publication date: December 20, 2001
    Inventors: Mary Ellen Rybak, Esther Helen Rose
  • Melanoma therapy
    Publication number: 20010038833
    Abstract: Methods for treating treatment-naive as well as treatment-experienced patients having melanoma to increase the progression-free survival time involving administering a therapeutically effective amount of pegylated interferon-alpha, e.g., preferably pegylated interferon alpha-2b, as adjuvant therapy to definitive surgery are disclosed.
    Type: Application
    Filed: July 12, 2001
    Publication date: November 8, 2001
    Inventors: Mary Ellen Rybak, Esther Helen Rose